Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:47 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 4,560 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: assessment only control Clear all

Conditions: Alopecia Areata
Interventions: Upadacitinib, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 12 Years to 63 Years
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 78
States / cities: Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 63 more

Conditions: Skin Laxity
Interventions: Percutaneous Radiofrequency single treatment; Device
Lead sponsor: ThermiGen, LLC; Industry
Eligibility: 35 Years to 65 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Montclair, New Jersey

Conditions: Dental Pain
Interventions: Pre-Op pregabalin, Pre-Op Placebo 1, Post-Op pregabalin, Post-Op Placebo 1, Post-Op Placebo 2, Post-Op acetaminophen; Drug
Lead sponsor: Nevakar, Inc.; Industry
Eligibility: 17 Years to 55 Years
Enrollment: 115 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Infection, Human Immunodeficiency Virus
Interventions: GSK2838232, Placebo, Ritonavir; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Depression, End Stage Renal Disease
Interventions: Engagement Interview, Cognitive Behavioral Therapy, Antidepressant Drug Therapy; Behavioral · Drug
Lead sponsor: University of Washington; Other
Eligibility: 21 Years and older
Enrollment: 184 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 3
States / cities: Albuquerque, New Mexico • Dallas, Texas • Seattle, Washington

Conditions: HIV Infections
Interventions: CARE+ Spanish computer counseling session, CARE+ Spanish brief computer risk assessment session; Other
Lead sponsor: New York University; Other
Eligibility: 18 Years and older
Enrollment: 556 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Systematic Lupus Erythematosus, Cutaneous Lupus Erythematosus
Interventions: Enpatoran, Placebo, Standard of care (SoC); Drug
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 15
States / cities: Upland, California • DeBary, Florida • Fort Lauderdale, Florida + 12 more

Conditions: Clostridium Difficile Infection Recurrence
Interventions: Bacillus velezensis DSM 33864, Placebo; Dietary Supplement
Lead sponsor: Novozymes A/S; Industry
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Royal Oak, Michigan

Conditions: Carbon Monoxide Poisoning
Interventions: Hyperbaric Oxygen (HBO2) - 3 sessions, Hyperbaric Oxygen (HBO2) - 1 session; Combination Product
Lead sponsor: Intermountain Health Care, Inc.; Other
Eligibility: 18 Years to 79 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2017
U.S. locations: 2
States / cities: Salt Lake City, Utah

Conditions: Inguinal Herniorrhaphy
Interventions: CPL-01, Naropin 150 MG Per 20 ML Injection, Placebo; Drug
Lead sponsor: Cali Pharmaceuticals LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 5
States / cities: Sheffield, Alabama • Phoenix, Arizona • Anaheim, California + 2 more

Conditions: Teen Pregnancy, Contraception Behavior, Sexually Transmitted Diseases, Reproductive Health, Sexual Risk Behavior
Interventions: Relationship Smarts Plus & Mind Matters, Relationship Smarts Plus alone, Preparing Adolescents for Young Adulthood (PAYA).; Behavioral
Lead sponsor: Trinity Church Inc.; Other
Eligibility: 13 Years to 19 Years
Enrollment: 945 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Miami Gardens, Florida

Conditions: Vulvovaginal Candidiasis
Interventions: NDV-3A, NDV-3, Placebo; Biological
Lead sponsor: NovaDigm Therapeutics, Inc.; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 188 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 20
States / cities: Phoenix, Arizona • Little Rock, Arkansas • San Diego, California + 17 more

Conditions: Non-small Cell Lung Cancer
Interventions: Suramin Drug:Docetaxel Drug: Carboplatin, Placebo Drug: Docetaxel Drug: Carboplatin; Drug
Lead sponsor: Optimum Therapeutics, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 2
States / cities: Chicago, Illinois • Richmond, Virginia

Conditions: Healthy Volunteers
Interventions: E2730, E2730-matched placebo; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Long Beach, California

Conditions: Depressive Disorder, Major
Interventions: Sertraline and Elzasonan Combination, Sertraline, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 262 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 4
States / cities: Beverly Hills, California • Norwich, Connecticut • New York, New York + 1 more

Conditions: Gout, Acute Gout Flare, Gout Flares
Interventions: ABP-745, Placebo; Drug
Lead sponsor: Atom Therapeutics Co., Ltd; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Acute Ischemic Stroke
Interventions: natalizumab, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 277 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 18
States / cities: Los Angeles, California • Sacramento, California • San Diego, California + 13 more

Conditions: Metastatic Pancreas Cancer, Locally Advanced Pancreatic Cancer, Pancreatic Adenocarcinoma
Interventions: EndoTAG-1, Gemcitabine; Drug
Lead sponsor: SynCore Biotechnology Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 16
States / cities: Corona, California • Atlanta, Georgia • Columbus, Georgia + 12 more

Conditions: Transcutaneous Oxygen Tension
Interventions: Celliant, Control; Device
Lead sponsor: Kristopher Washington; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 153 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Santa Monica, California

Conditions: Healthy Volunteers
Interventions: TAK-925, TAK-925 Placebo, Modafinil, Modafinil Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 40 Years · Male only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Keloid
Interventions: RXI-109, Placebo; Drug
Lead sponsor: RXi Pharmaceuticals, Corp.; Industry
Eligibility: 21 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 2
States / cities: Miami, Florida • St Louis, Missouri

Conditions: Ischemic Heart Failure
Interventions: JVS-100 15 mg dose Injection, Placebo Injection, JVS-100 30 mg dose injection; Biological
Lead sponsor: Juventas Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 16
States / cities: Birmingham, Alabama • Gainesville, Florida • Tampa, Florida + 12 more

Conditions: Cytomegalovirus Retinitis, HIV Infections
Interventions: Zidovudine, Sargramostim, Ganciclovir; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1992
U.S. locations: 4
States / cities: Los Angeles, California • Boston, Massachusetts • New York, New York + 1 more

Conditions: Cardiovascular Fitness, Physical Activity
Interventions: AFL Intervention, Wait-List Control; Behavioral
Lead sponsor: San Diego State University; Other
Eligibility: 6 Years to 11 Years
Enrollment: 149 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: San Diego, California

Search by objective public record fields.

A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata

Safety and Effectiveness Evaluation of the Device in Achieving Submental Lift

Dental Pain Study of Analgesics in Patients Undergoing Molar Removal

Single Dose Escalation Study of GSK2838232 in Healthy Subjects

A Trial of Sertraline vs. CBT for End-stage Renal Disease Patients With Depression {ASCEND}

A Spanish-Language Intervention to Enhance Routine HIV Patient Care Delivery [CARE+ Spanish]

A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)

Bacillus Velezensis DSM 33864 for Reduction of the Risk of Recurrent Clostridioides Difficile Infections

One vs. Three Hyperbaric Oxygen Treatments for Acute Carbon Monoxide Poisoning

A Phase 2, Randomized, Double-Blind, Dose Escalation Study in Postoperative Pain Open Inguinal Herniorrhaphy

Evaluation of an Adolescent Pregnancy Prevention Program; Relationship Smarts+ With Lessons From Mind Matters

Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis

Evaluation of Non-cytotoxic Suramin as a Chemosensitizer in Non-small Cell Lung Cancer

A Study to Assess the Safety and Tolerability of E2730 After Multiple Dose and the Food Effect After Single Dose in Healthy Participants

A Research Study to Compare the Treatments of a Combination of Elzasonan With Zoloft, to Zoloft Alone, or Placebo in People With Major Depressive Disorder (MDD)

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral ABP-745 Administration in Healthy Volunteers

Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke

EndoTAG-1+GEM vs GEM in Patients With Locally Advanced/Metastatic Pancreatic Adenocarcinoma Failed on FOLFIRINOX

Comparative Study Evaluating Performance of Celliant Fibers on Tissue Oxygenation

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of TAK-925 Study in Sleep-Deprived Healthy Adults

A Study to Evaluate the Effectiveness and Safety of RXI-109 on the Outcome of Keloid Excision Surgery in Healthy Adults

Study to Evaluate the Safety and Efficacy of JVS-100 Administered to Adults With Ischemic Heart Failure.

The Safety and Effectiveness of Ganciclovir Used Alone or in Combination With Granulocyte-Macrophage Colony Stimulating Factor in the Treatment of Cytomegalovirus (CMV) of the Eye in Patients With AIDS

Efficacy of the Athletes for Life Program to Promote Cardiovascular Health